Actineer Achieves Sustainable Radium-226 Recycling to Advance Reliable Commercial-Scale Production of Actinium‐225 for Global Radiopharmaceutical Programs

CHALK RIVER, Ontario--(BUSINESS WIRE)--Actineer, a joint venture between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM), today announced the successful completion of a closed-loop process to recycle Radium‐226 (Ra-226), the essential precursor material of Actinium-225 (Ac-225), a rare medical radioisotope that is highly sought-after for its role in the development of targeted alpha therapy (TAT) in oncology. This critical milestone supports reliable, long-term

CHALK RIVER, Ontario--(BUSINESS WIRE)--Actineer, a joint venture between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM), today announced the successful completion of a closed-loop process to recycle Radium‐226 (Ra-226), the essential precursor material of Actinium-225 (Ac-225), a rare medical radioisotope that is highly sought-after for its role in the development of targeted alpha therapy (TAT) in oncology. This critical milestone supports reliable, long-term